KFDA Denies Its Upcoming Decision to Disapprove on ‘Bacchus-S’

Published: 2004-12-27 06:57:00

Updated: 2004-12-27 06:57:00

Amid the continuing decision delays by the Korea Food and Drug Administration (KFDA) on the possible use of a trademark ‘Bacchus-S’, a quasi-medicine, requested by Dong-A Pharmaceutical, the KFDA made an official statement in response to a recent news release by a domestic press, where it suggest...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK